ERBB2 and non-small cell lung carcinoma: In addition to these evidences, novel genome-wide studies using liquid biopsy samples of 122 NSCLC patients under erlotinib (67.2%), gefitinib (11.5%) or afatinib (2.5%) treatment demonstrated a correlation between hypermethylation of regulatory regions of HOX genes and TKI resistance in those patients also having MET or HER2 amplifications.